

PCC Treatment for Hemophilia Patients With Inhibitor 2022PCC-A

NCT07406139

Status	RECRUITING
Phase	Phase 4
Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosed with hemophilia A with inhibitors. For high-responding patients (those who have previously had an inhibitor titer ≥ 5 BU), the inhibitor titer at enrollment must be ≥ 0.6 BU;
- Age between 12 and 65 years;
- At least three joint bleeding episodes within the past six months;
- Signed informed consent form.

Exclusion (6)

- Presence of other congenital or acquired bleeding disorders;
- Liver function tests (ALT, AST) > 2.5 times the upper limit of normal, or renal function tests (BUN, Cr) > 1.5 times the upper limit of normal;
- Currently receiving immune tolerance induction (ITI) therapy with an inhibitor titer ≤ 5 BU;
- History of thrombotic events;
- Known history of drug allergy, asthma, urticaria, or other allergic conditions;
- ... and 1 more (see full listing online)

Locations (1 total)

Institute of haematology and Blood diseases hospital, Tianjin, Tianjin Municipality, China